AB0676 FEARS AND HOPES DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1)

Background: The first wave of the COVID-19 pandemic led to a rapidly evolving global crisis characterized by major uncertainty. Objectives: objective is assess COVID-19-related fears and hopes in patients with rheumatic musculoskeletal diseases (RMDs) during pandemic. Methods: REUMAVID an international collaboration Health & Territory Research group at University Seville, together multidisciplinary team including patient organisations rheumatologists. This cross-sectional study consisting online survey gathering data from 1,800 diagnosis 15 RMDs recruited Cyprus, France, Greece, Italy, Portugal, Spain and, United Kingdom. Data are collected two phases, phase between April July 2020, second 2021. Participants rated series (infection, medication consequences, lack medication, impact on healthcare, job loss, civil disorder) Likert scale zero (“no concern all”) five (“extremely concerned”) their (treatment/vaccine availability, going outside, travel, economic situation, treatment continuation, health status) (“not hopeful hopeful”). Mann-Whitney Kruskal-Wallis tests were used analyse different according socio-demographics characteristics, disease status. Results: participated REUMAVID. most frequent was inflammatory arthritis (75.4%), mean age 52.6 years 80.1% female. important fear for healthcare (3.1 out 5), particularly those younger (3.0 vs 3.2, p=0.004), female gender (3.2 2. 9 men, p=0.003), experiencing greater pain 2.8, p=0.007), higher risk anxiety (3.3 2.9 without anxiety, p<0.001) depression depression, p<0.001). possible anti-rheumatic development severe if they became infected COVID-19,was mostly feared (2.8 receiving biological therapy 2.5 not therapy, or underlying (2.9 2.6 p=0.007). contracting due condition especially vasculitis who 2.5, p<0.001), using biologics (2. 2.7 no use, 2.4, be able continue as usual (3.7 taking (3.8 3.6 taking, p=0.026), better well-being worse well-being, p=0.021), risk, p=0.004) Hoping become maintain same status, older (3.6 3.4 p=0.018) (3.4 p=0.005), p=0.006). Another hope availability vaccine COVID-19, which 3.0 p<0.001; Figure 1). Conclusion: outstanding expressed European its while greatest treatment. Younger reported more hopeful. Those had associated In addition, mental disorders presented less hopes. 1. Fears Hopes participants Acknowledgements: supported Novartis Pharma AG. We would like thank all that completed well including: Cyprus League Against Rheumatism (CYPLAR) Association Française de Lutte Anti-Rhumatismale (AFLAR) Hellenic (ELEANA) Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) Portuguese Rheumatic Diseases (LPCDR), Spanish Federation Spondyloarthritis Associations (CEADE), Patients’ Forum (FEP), UNiMiD, Rheumatology (LIRE), Andalusian (LIRA), Catalonia Galician Spain, National Axial Society (NASS), Rheumatoid Arthritis (NRAS) Action Disclosure Interests: Marco Garrido-Cumbrera: None declared, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda UCB, Consultant of: Pfizer Grant/research support from: Janssen Laura Christen Employee AG, Loreto Carmona: José Correa-Fernández: Sergio Sanz-Gómez: Pedro Plazuelo-Ramos: Dale Webb UCB., Clare Jacklin Abbvie, Amgen, Eli Gilead, Roche, Sanofi Shantel Irwin: LAURENT GRANGE: Souzi Makri GSK Bayer., Elsa Mateus Lilly Sanofi, Grünenthal S.A., MSD, Medac, Janssen-Cilag, Pharmakern, GAfPA., Serena Mingolla: KATY ANTONOPOULOU: Victoria Navarro-Compán BMS, UCB